Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment

Atherosclerosis

Volumn 149, Issue 2, 2000, Pages 427-433

  Attia, Nebil ^a   Durlach, Vincent ^b   Cambilleau, Michèle ^c   Roche, Denis ^d   Girard Globa, Anik ^e  

^a University of Carthage   (Tunisia)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c HÔPITAL BROUSSAIS   (France)

^d Hopital Laennec   (France)

^e Lab Metabolisme Lipides CNRS U   (France)

Author keywords

Apo E; Chylomicrons; HDL; VLDL

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BEZAFIBRATE; BIGUANIDE DERIVATIVE; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAT INTAKE; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; ANALYSIS OF VARIANCE; ANTILIPEMIC AGENTS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; APOLIPOPROTEINS E; BEZAFIBRATE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROBABILITY;

EID: 0034063215     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00337-8     Document Type: Article

References (34)

1. Howard B.V. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 28:1987;613-628.
2. Grundy S.M., Vega G.L. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 83:1987;9-20.
3. Kosykh V.A., Podrez E.A., Novikov D.K., Victorov A.V., Dolbin A.G., Repin V.S., Smirnov V. Effect of bezafibrate on lipoprotein secretion by cultured human hepatocytes. Atherosclerosis. 68:1987;67-76.
4. Nikkilä E.A., Huttunen J.K., Ehnholm C. Effect of clofibrate on post-heparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metab Clin Exp. 26:1977;179-189.
5. Staels B., Vu-Dac N., Kosykh V.A., Saladin R., Fruchart J.-C., Dallongeville J., Auwerx J. Fibrates downregulate apolipoprotein C-III expression, independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest. 95:1995;705-712.
6. Schonfeld G., Geages P.I., Miller J., Reilly P., Witztum J. . Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metab Clin Exp. 28:1979;1001-1009.
7. Stocks J., Holdsworth G., Galton D.J. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III. Lancet. ii:1979;667-671.
8. Rees A., Stocks J., Sharpe C.R., Vella M.A., Shoulders C.C., Katz J., Jowett N.I., Bralle F.E., Galton D.J. Deoxyribonucleic acid polymorphism in the apolipoprotein A-I-C-III gene cluster. Association with hypertriglyceridemia. J Clin Invest. 76:1985;1090-1095.
9. Dammerman M., Sankuijl L.A., Halaas J., Chung W., Breslow J.L. An apolipoprotein C-III haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphism. Proc Natl Acad Sci USA. 90:1993;45-62.
10. Ito Y., Azrolan N., O'Connell A., Walsh A., Breslow J.L. Hypertriglyceridemia as a result of human apo C-III gene expression in transgenic mice. Science (Washington DC). 249:1990;790-793.
11. Aalto-Setälä K., Fisher E.A., Chen X., Chajek-Shaul T., Hayek T., Zechner R., Walsh R., Ramakrishnan R., Ginsberg H.N., Breslow J.L. Mechanism of hypertriglyceridemia in human apolipoprotein (Apo) C-III transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo C-III and reduced apo E on the particles. J Clin Invest. 90:1992;1889-1900.
12. Ginsberg H.N., Le N.-A., Wang-Iverson P., Gibson J.C., Rubinstein A., Goldberg I.J., Norum K.A. Apolipoprotein B metabolism in subjects with deficiency of apo C-III and apo A-I: evidence that apo C-III inhibits lipoprotein lipase in vivo. J Clin Invest. 78:1986;1287-1295.
13. Windler E., Chao Y., Havel R.J. Regulation of the hepatic uptake of triglyceride-rich lipoprotein in the rat. Opposing effects of homologous apolipoprotein E and individual C apolipoproteins. J Biol Chem. 255:1980;8303-8307.
14. Quarfordt S.H., Michalopoulos G., Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem. 257:1982;14642-14647.
15. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science (Washington DC). 258:1992;468-472.
16. Plump A.S., Smith J.D., Hayek T., Aalto-Setälâ K., Walsh A., Verstuift J.G., Rubin E.M., Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:1992;1-20.
17. Ebara T., Ramakrishnan R., Steiner G., Shachter N.S. Chylomicronemia due to apolipoprotein C-III overexpression in apolipoprotein E-null mice. Apolipoprotein C-III-induced hypertriglyceridemia is not mediated by effects on apoliprotein E. J Clin Invest. 99:1997;2672-2681.
18. De Silva H.V., Lauer S.J., Wang J., Simonet W.S., Weisgraber K.H., Mahley R.W., Taylor J.M. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulaton of apolipoprotein B48 in remnants that is corrected by excess apolipoprotein E. J Biol Chem. 269:1994;2324-2335.
19. Aalto-Setälä K., Weinstock P.H., Bisgaier C.L., Wu L., Smith J.D., Breslow J.L. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apo C-III transgenic mice. J Lipid Res. 37:1996;1802-1811.
20. Kowal R.C., Herz J., Weisgraber K.H., Mahley R.W., Brown M.S., Goldstein J.L. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 265:1990;10771-10779.
21. Chen M., Breslow J.L., Le W., Leff T. Transcriptional regulation of the apo C-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res. 35:1994;1918-1924.
22. Li W.W., Dammerman M.M., Smith J.D., Metzger S., Breslow J.L., Leff T. Common genetic variation in the promoter of the human apo C-III gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 96:1995;2601-2605.
23. Fredenrich A., Giroux L.M., Tremblay M., Krimbou L., Davignon J., Cohn J.S. Plasma lipoprotein distribution of apo C-III in normolipidemic and hypertriglyceridemic subjects: Comparison of the apo C-III to apo E ratio in different lipoprotein fractions. J Lipid Res. 38:1997;1421-1432.
24. Havel R.J., Kane J.P., Kashyap M.L. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J Clin Invest. 61:1973;1654-1665.
25. Kashyap M.L., Barnhart R.L., Srivastava L.S., Perisutti G., Allen C., Hogg E., Glueck C.J., Jackson R.L. Alimentary lipemia: plasma high-density lipoproteins and apolipoproteins C-II and C-III in healthy subjects. Am J Clin Nutr. 37:1983;233-243.
26. Attia N., Durlach V., Roche D., Paul J.L., Soni T., Zahouani A., Landron F., Labrousse F., Leutenegger M., Girard-Globa A. Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment. Eur J Clin Invest. 27:1997;55-63.
27. Cardin A.D., Kathleen R.W., Chao J., Margolins H.S., Donaldson V.H., Jackson R.L. Degradation of apolipoprotein B-100 of human plasma low density lipoprotein by tissue and plasma kallikreins. J Biol Chem. 259:1984;8522-8528.
28. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 31:1991;545-548.
29. Redgrave T.G., Carlson L.A. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. J Lipid Res. 20:1979;217-229.
30. Matthews J.N.S., Altman D.G., Campbell M.J., Royton P. Analysis of serial measurements in medical research. Br Med J. 300:1990;230-23531.
31. Curry M.D., McConathy W.J., Fesmire J.D., Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta. 6717:1980;503-513.
32. Le N.-A., Gibson J.C., Ginsberg H.N. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res. 29:1988;669-677.
33. Tornoci L., Scheraldi C., Li X., Ide H., Goldberg I.J., Le N.-A. Abnormal activation of lipoprotein lipase by non-equilibrating apo C-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. J Lipid Res. 34:1993;1793-1803.
34. Björkegren J., Hamsten A., Milne R.W., Karpe F. Alterations of VLDL composition during alimentary lipemia. J Lipid Res. 38:1997;301-314.